Super Micro Computer Inc vs BIO-TECHNE Corp — how do they compare? Super Micro Computer Inc trades at $38.6 (market cap $26.45B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Super Micro Computer Inc is far larger — about 2.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| SMCI | TECH | |
|---|---|---|
Market Cap | $26.45B | $11.34B |
Sector | Technology | Health |
52-Week High | $58.68 | $72.48 |
52-Week Low | $20.53 | $43.31 |
Enterprise Value | $31.92B | $11.36B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $40.26, up 1.69% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 12.35 and ROE of 26.53%, supported by AI-driven revenue growth and a record backlog. Recent news highlights strong AI infrastructure demand and insider selling of $7.7 million in shares.
Outlook remains positive given AI server demand and improving margins, but risks include cash flow volatility and competitive pressures. Analysts are mixed with a $40.57 consensus target, suggesting limited near-term upside from current levels amid execution and market sentiment risks.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Trailing returns across standard periods
Latest headlines on both assets
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →